Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02942927Not ApplicableCompleted

Team Approach to Polypharmacy Evaluation and Reduction

Role: collaborator

NCT03557944Not ApplicableUnknown

Team Approach to Polypharmacy Evaluation and Reduction (Pharmacy)

Role: collaborator

NCT02562352Not ApplicableCompleted

Team Approach to Polypharmacy Evaluation and Reduction

Role: collaborator

NCT02914197Not ApplicableUnknown

Giving Information on the Risks and Limitations of Mammography Screening (GIRLS)

Role: collaborator

All 4 trials loaded